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ABSTRACT
Objective: The objective of this selective EBM review of three composite studies is to determine
whether or not atomoxetine improves inattentiveness in adults with attention-deficit
hyperactivity disorder (ADHD)?
Study Design: A systematic review of three blinded randomized controlled trials (RCTs)
published between 2011 and 2021.
Data Sources: Research was gathered from PubMed and Embase in December 2020-February
2021 for the three RCTs, and supplemental articles were found in September through November
2021 from PubMed. All three RCTs were published in English and found in peer-reviewed
journals and were chosen based on their relevance to the topic question.
Outcome Measured: A reduction in inattentiveness while taking atomoxetine vs. placebo. This
was measured by the Conners’ Adult ADHD Rating Scale Investigator-Rated/Self-Report
Screening Version: Inattention Subscale (CAARS-Inv/S:SV IS) 3,5 and Brown Attention-Deficit
Disorder Scale (BADDS)4 for Adults before and after P.O. administration of placebo or
atomoxetine. The scales range from 0-27 with lower scores indicating milder symptoms and
higher scores suggesting greater severity of inattention.
Results: In all three RCTs, atomoxetine resulted in a significant reduction in inattentiveness
compared to placebo evidenced by symptom scales (p value < 0.001 in Durell et al. 3 and
Upadhyaya et al.5, and p value < 0.05 in Brown et al.4). Mean changes from baseline
inattentiveness scores maintained 4.4 points of difference between atomoxetine and placebo
groups in the article by Durell et al.,3 2.2 points in Brown et al.4, and 1.9 points of difference in
the RCT by Upadhyaya et al.5 All p-values were statistically significant and all three RCTs had a
moderate treatment effect.
Conclusions: All three reviewed studies show that atomoxetine resulted in significantly reduced
inattentiveness in adults with ADHD. The findings suggest atomoxetine is more effective than
placebo for improving focus in the mature ADHD brain. Future studies may cover the
recommended treatment duration for atomoxetine in adults, the sufficiency of atomoxetine
monotherapy for the treatment of ADHD in adults, and long-term side effects of chronic
atomoxetine use in people aged ≥ 18 years old.
Key Words: atomoxetine, adults with ADHD, inattention/inattentiveness

DeFelice |ATOMOXETINE FOR INATTENTION 1
INTRODUCTION
Attention-deficit hyperactivity disorder (ADHD) is a cognitive affliction that causes
difficulty with self-regulation and focus in multiple settings. More than 6 million children in the
U.S. have been diagnosed with ADHD, and this does not include disadvantaged people unable to
make appointments for evaluation and diagnosis. 1,2 It is the most common neurodevelopmental
condition in children2 and over half of children diagnosed with ADHD have symptoms that
persist into adulthood.3,4 The etiology and pathophysiology of ADHD are not fully understood,
but it is proposed that genetic and environmental factors contribute and the neurotransmitter
norepinephrine is affected. People with ADHD may be distractible, inattentive, forgetful,
hyperactive and impulsive, causing difficulty in academics and employment, alcohol and drug
use disorders, and car or work accidents resulting in emergency room visits. 1-5 Per a 2017 NCHS
Data Brief, ADHD accounts for roughly 6 million medical visits per year, 2 an amount which
does not include adults or visits for ADHD’s common comorbidities nor accidents due to
ADHD. Commonly comorbid conditions include anxiety disorders, tics, personality disorders,
and drug addiction.1,3 Patients with ADHD may be seen in psychiatric facilities, addiction
clinics, primary care offices, emergency departments, and more. Annual costs for ADHD in the
U.S. are estimated to be between $38 billion and $72 billion. 1
Pharmacotherapy is of great importance in the management of ADHD. Treatments for
children with ADHD have been thoroughly studied, however the effectiveness of such treatments
in adults is not well-known. Stimulants such as amphetamine/dextroamphetamine and
methylphenidate are first-line pharmacotherapy for ADHD and are the usual method of treatment
for ages > 6 years old. They are effective yet have high addiction potential and unpleasant side
effects.5 Behavioral therapy or educational support are common adjunctive options; they lack
side effects but are less effective alone and are usually paired with stimulants. Alternative
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medications include alpha 2-agonists guanfacine and clonidine, and the SNRI atomoxetine; these
can be used alone or in combination with stimulants. The alpha 2-agonists are more commonly
used for children with behavioral problems. Atomoxetine is an FDA-approved non-stimulant
ADHD medication that works by selectively inhibiting presynaptic norepinephrine reuptake in
the prefrontal cortex. It is vastly more tolerable than stimulants and has no addiction potential.
Atomoxetine has been proven to work in pediatric populations, 4 but the extent to which it
benefits adults has not been as thoroughly studied. This paper examines the results of three
randomized controlled trials (RCTs) that sought to determine the effectiveness of atomoxetine at
reducing functional impairment in adults with ADHD.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Does
atomoxetine improve inattentiveness in adults with ADHD?”
METHODS
Studies were selected based on reliability, applicability to the patient-oriented outcome in
question and having a primary RCT design. All articles needed to be blinded, in English, and
published in peer-reviewed journals no earlier than a decade prior to the start of this study’s
research. Their population, problem and comparison investigated needed to comprise adults
meeting DSM-IV-TR criteria for ADHD with inattentiveness symptoms treated with the clinical
intervention of either atomoxetine or placebo alone. The outcome of interest was improved
executive function, specifically including change in attentiveness after treatment. Chosen studies
were found on PubMed and Embase in late 2020 through early 2021 using the following
keywords in searches: atomoxetine, adults, ADHD, executive function, and outpatients. All three
RCTs were published after 2010 and were in English; Upadhyaya et al.5 was also published in
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Spanish. Any studies only evaluating children or containing the terms “meta-analysis”/
“systematic review” in the title or study design were excluded.
Statistical assays used in the articles included analyses of covariance to calculate the
Least Squares mean change from baseline in the CAARS:SV for Durell et al. 3 and Upadhyaya et
al.5, standard deviations, confidence intervals, and mean change from baseline in BADDS scale
in Brown et al.4 P-values were reported. Table 1 depicts each article’s participant demographics.
Table 1. Demographics & Characteristics of Included Studies
Study

Type

Pts

Age

Inclusion Criteria

Exclusion Criteria

Durell3
2013 (1)

Double
blind
RCT

445

Adults
18 to
30
years
of age

Pts outside of the age
range, or who had
Symptom Checklist
scores that changed by >
25% between Visits 1 &
2, or who carried certain
psychiatric diagnoses.b

Brown4
2011 (2)

Double
blind
RCT

501

Adults
18 to
54
years
of age

18-30 y/o’s who met
DSM-IV-TR ADHD
criteria w/
CGIADHDS score ≥4, (+) scores
on symptom scales,a
and functional
impairment confirmed
by clinical interview
18-54 y/o’s who met
DSM-IV-TR ADHD
criteria w/
CGIADHDS score ≥4, (+) scores
on symptom scales,c
and resultant
functional impairment
confirmed by clinical
interview

Upadhya
ya5 2013
(3)

Double
blind
RCT,
Withdr
awal
subtype

524

Adults
18 to
50
years
of age

a

18-50 y/o’s who met
DSM-IV-TR ADHD
criteria w/
CGIADHDS score ≥4 at Visits 1
& 2, who responded to
previous tx w/
atomoxetine, had (+)
scores on symptom
scalese and functional
impairment confirmed
by clinical interview

Pts outside the age range,
or who had Symptom
Checklist scores that
changed by > 25%
between Visits 1 & 2,
non-responders to other
ADHD meds, being in a
past atomoxetine study,
regular use of specific
meds or certain psych.
diagnoses.d
Pts outside of the age
range, or who were nonresponders to
atomoxetine in clinical
trials, or who met DSMIV-TR diagnostic criteria
for certain psychiatric
disorders.f

W/
D
20
0

INT

17
7

25-100
mg
atomoxetine
PO vs.
placebo,
x6
months

17
5

40-100
mg
atomoxetine
PO vs.
placebo,
x 25
weeks

40-100
mg
atomoxetine
PO vs.
placebo,
x 12
weeks

CAARS, Adult ADHD Clinician Diagnostic Scale version 1.2. bMajor depression, panic disorder, PTSD, an eating disorder, substance abuse or
dependence, OCD in the past or present, bipolar disorder, or psychosis.3 cAdult ADHD Investigator Symptom Rating Scale. dRegular use of
antiepileptics for seizures or any psychotropic medication routinely, bipolar disorder or psychosis, and pregnant or breastfeeding women, or
people with uncontrolled hypertension.4 eCAARS. fMajor depression, bipolar disorder, history of psychosis, current panic disorder, current social
phobia, or current generalized anxiety disorder, current alcohol consumption, substance abuse or use disorder or substance dependence. 5
Parentheticals with author names denote the study cited.

OUTCOME MEASURED
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The outcome in focus was decreased inattentiveness on atomoxetine vs. placebo. This
was measured by the Conners’ Adult ADHD Rating Scale, Screening Version: Inattention
Subscale (CAARS-SV: IS) Self-Report version Upadhyaya et al. 5 and the Investigator-Rated
version of the CAARS-SV: IS in Durell et al.,3 and the “focus” subset of the Brown AttentionDeficit Disorder Scale (BADDS) for Adults in Brown et al.4 These focus/inattention subscales
are completed by the participants and each have 9 symptom questions with answers graded by
severity from 0-3 points. Total scores, then, range from 0-27 with lower scores indicating milder
symptoms and higher scores suggesting greater severity of inattention. If statistically significant,
any change in the difference in points scored for inattention between the atomoxetine and the
control group from before and after taking the capsule is evidence that atomoxetine had some
effect on inattention that was different from the placebo’s effect. Even a score improvement by
just 3 points for example could indicate complete eradication of one of the inattention symptoms.
The three studies’ results show patient-reported consequences of an ADHD treatment which the
patients in question experienced in their daily lives and which providers should pay attention to
for treatment purposes.
RESULTS
All three studies enrolled adults 18 years and older who met DSM-IV-TR and Adult
ADHD Diagnostic criteria for ADHD and evaluated changes in their related symptoms’ severity
while taking up to 100 mg oral atomoxetine or placebo. The atomoxetine dosage in Brown et al. 4
was 25-100 mg and was 40-100 mg atomoxetine in the articles by Durell et al. 3 and Upadhyaya
et al.5 Outcomes in each of the blinded RCTs were not dichotomous data nor able to be
converted to dichotomous form, therefore summary statistics such as “Risk Ratio” and “Number
needed to treat/harm” etc. were incalculable.
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3

The study by Durell et al. compared subjects’ ADHD symptom scores after taking 40100 mg atomoxetine or placebo for 12 weeks. Mean score change on the CAARS was the
primary efficacy measure and inattention was the primary symptom in question. This study
employed a 2 week double blinded “sham placebo lead-in period” 3 wherein all participants were
started on placebo unbeknownst to the scientists and participants and then half of the participants
were switched to atomoxetine at a time unknown to them nor the investigators. Subjects were
randomly assigned to groups in a 1:1 ratio by computer program and were analyzed within these
groups. Participants were from the U.S. and were mostly white males with similar education
levels, though some females were included; see Table 1. Overall, 220 participants received
atomoxetine and 225 received placebo.
Treatment effect was moderate in Durell et al.3 according to Cohen’s d score.8 The
participants’ average baseline was 21.6 on the CAARS-SV: IS and after intervention the
atomoxetine group’s score decreased to 14.6, though the placebo’s only decreased to 16.8. That
is, the atomoxetine groups’ inattention symptom scores improved by roughly 7 points on a 0–27point scale. Mean change from baseline was 4.4 points of difference between groups after 12
weeks, see Table 2; p-value < 0.001. The narrow 95% CI (-3.51-1.19) including zero
demonstrates there may be uncertainty regarding treatment effect; however, based on the
significant improvement in inattention scores with confidence intervals not crossing zero
demonstrated by the other scales in the article with the same treatment effect, it can be deduced
this risk is minimal and the results remain clinically meaningful per Durell et al. 3
Table 2. Comparison of Symptom Score Change between Groups from Baseline to Week 12
Measured on CAARS-Inv-SV: Inattention Subscale (in Durell et al. 3)
Group

Baseline- Mean (SD) Endpoint- Mean (SD) Mean Change from Baseline- LS Mean ± SE

P-value

Atomoxetine 21.6 (3.4)

14.6 (6.4)

-7.6 ± 0.5

P < 0.001

Placebo

16.8 (6.3)

-5.2 ± 0.5

P < 0.001

21.6 (3.6)
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Treatment-related adverse events, weight and vital signs were monitored at each visit and
ECG readings were recorded for patients at the first and last visit in Durell et al., 3 and any
subject who received one or more doses of atomoxetine underwent safety analyses.
Discontinuation due to side effects (n = 27) was more common in the atomoxetine group (n = 21,
9.5%) compared to placebo group (n = 6, 2.7%; P = 0.003). Adverse effects included irritability,
fatigue, decreased appetite, insomnia, xerostomia, nausea and dyspepsia. 3 Other discontinuations
were from loss to follow-up (n = 97) or participant decision (n = 54). Ultimately 52.3% of
subjects taking atomoxetine and 57.8% of subjects taking placebo completed the study, and the
completion rate disparity between groups was not statistically significant (P = 0.25). 3
The study by Brown et al.4 compared subjects’ ADHD symptom scores on the BAADS
scale after placement on atomoxetine 25-100 mg/day or placebo for 26 weeks. The primary
efficacy measure was the AISRS and secondary measure was the BAADS scale; the primary
outcome of interest for the review regarded the “focus” component of the BAADS. The patient
cohort was from the U.S. and maintained similar demographics such as education level, gender,
and age across groups.4
In Brown et al.,4 participants were randomly assigned 1:1 by computer system in a
blinded manner to atomoxetine or placebo groups after a washout period from Visit 1-2. Overall,
250 people received atomoxetine and 251 received placebo. A total of 37.6% of patients taking
atomoxetine and 44.6% of patients taking the placebo completed the study. Reasons for
discontinuation included lack of improvement in the placebo group and treatment-related adverse
events from atomoxetine in the intervention group such as xerostomia, nausea, weight loss,
anorexia, fatigue, urinary hesitation, sexual dysfunction, and tachycardia. Heart rate increased
significantly in the atomoxetine vs. placebo group (p <0.001). There were significantly more
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discontinuations due to adverse events in the atomoxetine group (17.2%) compared to placebo
(5.6%) (p < 0.001).4
Treatment effect was moderate and for the BAADS score LS mean difference the 95%
confidence interval was -12.67 to -3.25 in Brown et al. 4 The participants’ baseline focus score on
the BAADS averaged 21.3 and after treatment decreased by 7.49 in the atomoxetine group and
5.33 in the placebo group.4 Mean change from baseline was 2.2 points of difference between
groups, with p-value <0.001 within groups and p-value < 0.002 between groups, see Table 3.
Table 3. Comparison of Symptom Score Change between Groups from Baseline to Week 26 Measured
on BAADS Scale’s Focus Cluster (in Brown et al. 4)
Groups

Baseline- Mean ± SD Endpoint- Mean ± SD Mean Change from Baseline- Mean ± SD

Atomoxetine 21.27 ± 3.98

13.78 ± 6.71

Placebo

15.92 ± 7.09

21.26 ± 4.22

P-value

-7.49 ± 6.84

P < 0.001

-5.33 ± 6.73

P < 0.001

5

Study period 3b of Upadhyaya et al.’s research was a randomized withdrawal trial which
is a type of RCT in which only previous responders to atomoxetine were permitted into the
design. This portion compared subjects’ ADHD symptom scores after taking up to 80-100 mg
atomoxetine or placebo for 25 weeks. The primary efficacy measure was maintenance of
response and a secondary measure was the CAARS-Inv/S:SV; the primary outcome of interest
regarded the CAARS-SV: IS. Patient demographics were similar across groups as most were
white European males, see Table 1.
Atomoxetine responders able to maintain response in trials of 40-100 mg were
randomized by undisclosed methods in a 1:1 ratio to atomoxetine or placebo in Upadhyaya et al. 5
The atomoxetine group had 266 participants and a study completion rate of 69.2% while the
placebo group had 258 and a completion rate of 64.0%. Reasons for discontinuation in the
placebo group were lack of treatment efficacy and failing to meet maintenance criteria. Patients
discontinued in the atomoxetine trial due to adverse events (n = 348), and reasons for leaving in
both groups included physician or patient decision, loss to follow up, or protocol violations.
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Treatment effect size was moderate in Upadhyaya et al.5 Significantly more patients who
received atomoxetine than placebo maintained sufficient treatment response overall (64.3% vs
50.0%, p < 0.001) and up to the 25 week endpoint (p < 0.05). Lower symptom severity was
shown by LS mean in the CAARS-Inv:SV IS scores between atomoxetine and placebo-treated
patients (p < 0.001). CAARS-S:SV IS is a smaller version and so the ADHD patients’ baseline
inattention score of 8.6 was still high, and the atomoxetine group’s score decreased by 0.7 points
while the placebo group’s score actually increased by 1.2. Mean change from baseline was 1.9
points of difference between groups (p-value <0.001).5 See Table 4 below.
Table 4. Comparison of Symptom Score Change between Groups from Start of Withdrawal
Period to Week 25 Measured on CAARS-S:SV Inattention subscale (in Upadhyaya et al. 5)
Groups

Baseline- Mean (SD) Endpoint- Mean (SD) Mean Change from Baseline- LS Mean (SE)

P-value

Atomoxetine 8.7 (4.6)

7.7 (4.6)

-0.7 (0.4)

P < 0.001

Placebo

9.3 (6.1)

1.2 (0.4)

P < 0.001

8.5 (5.1)

DISCUSSION
Attention-deficit hyperactivity disorder (ADHD) is a condition that affects patients’ daily
lives and productivity in a detrimental way by disturbing their executive functioning. Executive
function includes the brain’s ability to maintain attention, concentrate, self-regulate and stay
organized.4,5 Over half of children diagnosed with ADHD have symptoms of impaired executive
function that persist into adulthood,3,4 but treatments for adults have been less thoroughly
studied. ADHD has no cure but it is manageable by therapies combined with medications, the
primary type of which is stimulants such as methylphenidate and dexamphetamine. These are
first-line but have undesirable side effects, supporting the need for alternative pharmacologic
agents. One such agent is atomoxetine hydrochloride, a non-stimulant presynaptic selective
norepinephrine reuptake inhibitor that is FDA-approved for the treatment of ADHD in people
above 6 years old.
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Unlike the traditional treatment, atomoxetine has no addiction potential due to its action
in the prefrontal cortex as opposed to the nucleus accumbens, so it is preferred for patients at risk
for substance abuse.6 Atomoxetine also treats anxiety disorders, tic disorders, dyslexia, and
elimination disorders which may be comorbid.6 It lowers potential for relapse and also may be
useful in treating symptoms of Parkinson's disease and autism spectrum disorders. 5,6 Due to
fewer side effects, atomoxetine is reported to promote a greater quality of life. 6 Negative side
effects are usually mild and include xerostomia, dizziness, nausea, tachycardia, dyspepsia,
fatigue, erectile dysfunction, decreased appetite and weight loss, and urinary hesitation. 3,4
Atomoxetine previously carried a black box warning for increased suicide risk in children, but
this has since been debunked.7
This review evaluated atomoxetine’s effectiveness for decreasing inattention symptoms
in adults meeting DSM-IV-TR criteria for ADHD in a primary care setting. This was
accomplished through analysis of results from three double-blinded RCTs with moderate effect
sizes comparing atomoxetine with placebo treatments in the U.S. and Europe. All three RCTs
demonstrated statistically significant improvements in inattention scores through the BAADS or
CAARS after several weeks of treatment (p < 0.001).3,4,5 This proved that atomoxetine is more
effective than placebo for improving inattention symptoms in adults with ADHD.
Compliance: In Brown et al.4 compliance was measured at each visit by directly asking the
patients and by checking the amount of unused and used drug. Compliance was positive if
patients took their prescribed dose ≥70% of the time.4 It was defined the same way in Upadhyaya
et al.,5 and was measured by maintenance of the patients’ initial atomoxetine responses.
Compliance was about 82% in both groups in the withdrawal phase by Upadhyaya et al., 5 a high
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number due to the fact that only atomoxetine responders fully compliant with their doses and
protocols in previous trials were involved.5 Compliance was not addressed in Durell et al.3
Validity: Sample sizes were adequate. Blinding was achieved and the control and intervention
groups were similar at the start in all studies. The randomization allocation was concealed from
those enrolling subjects into the trial in Durell et al. 3 and Brown et al.,4 but it was not so in
Upadhyaya et al.5 This along with the fact that data were analyzed in their assigned groups in
Durell et al.3 but not in Brown et al.4 or Upadhyaya et al.5 could impair the validity of the latter
two studies. Follow-up was sufficiently long in all three RCTs. At the conclusion of the trials,
losses to follow-up were not < 20% in all three articles but a worst-case analysis was performed
on all subjects lost to follow-up in each,3,4,5 decreasing opportunity for bias.
Outliers: Upadhyaya et al.5 included adults over the age of 30 and up to 50, unlike Durell et al. 3
and Brown et al.4 It is unclear how this may have affected the results until further studies are
completed comparing response to atomoxetine in older vs. younger adults, though previous
studies suggest a slightly greater response in young adults to ADHD treatment per Durell et al. 3
It is important to note for treatment purposes that stimulants, though first-line, do not always
work for all patients with ADHD. Therefore, more knowledge about atomoxetine use for ADHD
is relevant for patient care. Brown et al. 4 excluded patients who had previous nonresponse to
stimulant medications, while Durell et al.3 included such patients; one-third of the participants in
Durell et al.3 had tried stimulants in the past. Upadhyaya et al. 5 only included participants who
were previous responders to atomoxetine, which is different from the other two studies.
Limitations: Each study had limitations. Most participants were white in all the studies, which
does not accurately represent the overall population of adults with ADHD. Lower completion
rate in Durell et al.3 (~55%) and Brown et al.4 (~41%) than other related studies reduced the
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statistical power of these results. The higher completion rate in Upadhyaya et al. 5 (~67%) can be
explained by that study’s inclusion of only atomoxetine-responders, whereas not all patients
receiving atomoxetine in the other articles were guaranteed to have a clinical response. In
addition, the use of a single self-rating scale for patients with ADHD in each of the three studies
makes the presence of a self-reporting bias possible. In Upadhyaya et al., 5 LOCF was only
carried forward to visit 18 out of 25, therefore some follow-up data may be missing. Relapse
post-atomoxetine might not always be immediate, and therefore some cases of relapse may have
been missed in Upadhyaya et al.5 Furthermore, there was not a washout period between the
Double-Blind Maintenance of Response Period and the Randomized Withdrawal Period in the
aforementioned study, so patients previously on atomoxetine who were then switched to placebo
in the withdrawal period may have had lingering effects of atomoxetine still impacting their
symptom scores. This study5 also did not account for how patients’ environmental changes in the
trial may have impacted their symptom scores. For example, a patient who previously had
improvement in executive function while taking atomoxetine may feel more positively about his
or her capacity to overcome symptoms in the withdrawal phase, and thereby may perform better
regardless of whether they are receiving atomoxetine or placebo. 5
Generalizability: In Durell et al.3 and Brown et al.,4 the results are generalizable to Caucasian
adult patients with ADHD including inattentive-type symptoms, but may not be generalizable to
their non-white counterparts. In Upadhyaya et al.,5 the generalizability is also limited to
atomoxetine responders, and in Brown et al.4 the generalizability is also limited by exclusion of
adults who failed previous ADHD medications. Though both the treatment and placebo groups
experienced a decrease in problems focusing in Brown et al., 4 the atomoxetine group
experienced a greater decrease that was statistically significant (p <0.001), suggesting

atomoxetine is more effective to improve focus than placebo. Furthermore, Upadhyaya et al. 5
showed that withdrawal of atomoxetine treatment resulted in relapse of inattentiveness
symptoms.
CONCLUSION
Each of the three trials3,4,5 in this review demonstrated statistically significant
improvements in inattention symptoms on atomoxetine vs. placebo, making the answer to this
paper’s clinical question “Does atomoxetine improve inattentiveness in adults with ADHD?” a
resounding “yes.” Atomoxetine was found to improve quality of life for these adult patients.
Future studies are warranted for comparing the results of atomoxetine treatment in adults under
vs. over 50 years old, and subsequent studies may be useful for determining the recommended
treatment duration of atomoxetine for adults with ADHD, the potential and timeline for relapse
in older adults, and long-term side effects of chronic atomoxetine use in people ≥ 18 years old.
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